Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

REGENXBIO Inc. (RGNX) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

REGENXBIO Inc. (RGNX), most recent 12 months reported: revenue $174.48M, net loss $196.43M, free cash flow -$249.67M. Latest balance sheet on file: liquid cash $105.52M. From SEC filings. Others in Biological Products, (No Diagnostic Substances): ADAPTIVE BIOTECHNOLOGIES CORPORATION · VERICEL CORPORATION · Vir Biotechnology, Inc. · Vaxart, Inc. · IMMUNITYBIO, INC. · Beam Therapeutics Inc. · AGENUS INC · ATARA BIOTHERAPEUTICS, INC.

Stock screener

Watchlist